vs
MESA LABORATORIES INC（MLAB）与IMPINJ INC（PI）财务数据对比。点击上方公司名可切换其他公司
IMPINJ INC的季度营收约是MESA LABORATORIES INC的1.1倍（$74.3M vs $65.1M），IMPINJ INC净利率更高（11.2% vs 5.6%，领先5.6%），MESA LABORATORIES INC同比增速更快（3.6% vs -0.0%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $2.2M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -14.9%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
Impinj Inc.是一家美国射频识别（RFID）设备及软件提供商，成立于2000年，总部位于华盛顿州西雅图，源自加州理工学院Carver Mead与Chris Diorio的研究成果。公司主营EPC Class 1 Gen 2无源超高频RFID芯片、读写器、读写器芯片、天线，以及芯片编码、业务数据采集相关的软件应用，为各行业RFID应用提供全链路产品支持。
MLAB vs PI — 直观对比
营收规模更大
PI
是对方的1.1倍
$65.1M
营收增速更快
MLAB
高出3.7%
-0.0%
净利率更高
PI
高出5.6%
5.6%
自由现金流更多
MLAB
多$15.8M
$2.2M
两年增速更快
MLAB
近两年复合增速
-14.9%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $74.3M |
| 净利润 | $3.6M | $8.3M |
| 毛利率 | 64.2% | 49.1% |
| 营业利润率 | 12.2% | 30.5% |
| 净利率 | 5.6% | 11.2% |
| 营收同比 | 3.6% | -0.0% |
| 净利润同比 | 316.6% | — |
| 每股收益（稀释后） | $0.65 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABPI
| Q1 26 | — | $74.3M | ||
| Q4 25 | $65.1M | $92.8M | ||
| Q3 25 | $60.7M | $96.1M | ||
| Q2 25 | $59.5M | $97.9M | ||
| Q1 25 | $62.1M | $74.3M | ||
| Q4 24 | $62.8M | $91.6M | ||
| Q3 24 | $57.8M | $95.2M | ||
| Q2 24 | $58.2M | $102.5M |
净利润MLABPI
| Q1 26 | — | $8.3M | ||
| Q4 25 | $3.6M | $-1.1M | ||
| Q3 25 | $2.5M | $-12.8M | ||
| Q2 25 | $4.7M | $11.6M | ||
| Q1 25 | $-7.1M | $-8.5M | ||
| Q4 24 | $-1.7M | $-2.7M | ||
| Q3 24 | $3.4M | $221.0K | ||
| Q2 24 | $3.4M | $10.0M |
毛利率MLABPI
| Q1 26 | — | 49.1% | ||
| Q4 25 | 64.2% | 51.8% | ||
| Q3 25 | 61.5% | 50.3% | ||
| Q2 25 | 62.0% | 57.8% | ||
| Q1 25 | 61.8% | 49.4% | ||
| Q4 24 | 63.3% | 50.5% | ||
| Q3 24 | 61.3% | 50.0% | ||
| Q2 24 | 64.0% | 56.1% |
营业利润率MLABPI
| Q1 26 | — | 30.5% | ||
| Q4 25 | 12.2% | -2.9% | ||
| Q3 25 | 7.8% | 0.7% | ||
| Q2 25 | 5.1% | 11.1% | ||
| Q1 25 | 2.4% | -12.9% | ||
| Q4 24 | 9.2% | -3.9% | ||
| Q3 24 | 6.1% | -0.8% | ||
| Q2 24 | 9.6% | 8.8% |
净利率MLABPI
| Q1 26 | — | 11.2% | ||
| Q4 25 | 5.6% | -1.2% | ||
| Q3 25 | 4.1% | -13.3% | ||
| Q2 25 | 8.0% | 11.8% | ||
| Q1 25 | -11.4% | -11.4% | ||
| Q4 24 | -2.7% | -2.9% | ||
| Q3 24 | 5.9% | 0.2% | ||
| Q2 24 | 5.8% | 9.7% |
每股收益（稀释后）MLABPI
| Q1 26 | — | $0.14 | ||
| Q4 25 | $0.65 | $-0.02 | ||
| Q3 25 | $0.45 | $-0.44 | ||
| Q2 25 | $0.85 | $0.39 | ||
| Q1 25 | $-1.30 | $-0.30 | ||
| Q4 24 | $-0.31 | $-0.06 | ||
| Q3 24 | $0.63 | $0.01 | ||
| Q2 24 | $0.62 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $131.8M |
| 总债务越低越好 | $68.4M | $241.5M |
| 股东权益账面价值 | $186.7M | — |
| 总资产 | $434.8M | $502.5M |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资MLABPI
| Q1 26 | — | $131.8M | ||
| Q4 25 | $29.0M | $175.3M | ||
| Q3 25 | $20.4M | $190.1M | ||
| Q2 25 | $21.3M | $193.2M | ||
| Q1 25 | $27.3M | $147.9M | ||
| Q4 24 | $27.3M | $164.7M | ||
| Q3 24 | $24.3M | $170.3M | ||
| Q2 24 | $28.5M | $220.2M |
总债务MLABPI
| Q1 26 | — | $241.5M | ||
| Q4 25 | $68.4M | $280.9M | ||
| Q3 25 | $69.4M | $280.4M | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | $283.5M | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — |
股东权益MLABPI
| Q1 26 | — | — | ||
| Q4 25 | $186.7M | $209.2M | ||
| Q3 25 | $178.5M | $195.0M | ||
| Q2 25 | $172.5M | $187.7M | ||
| Q1 25 | $159.8M | $160.6M | ||
| Q4 24 | $155.2M | $149.9M | ||
| Q3 24 | $161.5M | $136.1M | ||
| Q2 24 | $150.7M | $117.0M |
总资产MLABPI
| Q1 26 | — | $502.5M | ||
| Q4 25 | $434.8M | $545.2M | ||
| Q3 25 | $430.4M | $516.5M | ||
| Q2 25 | $435.7M | $508.8M | ||
| Q1 25 | $433.3M | $479.8M | ||
| Q4 24 | $433.3M | $489.1M | ||
| Q3 24 | $454.1M | $476.4M | ||
| Q2 24 | $440.4M | $446.1M |
负债/权益比MLABPI
| Q1 26 | — | — | ||
| Q4 25 | 0.37× | 1.34× | ||
| Q3 25 | 0.39× | 1.44× | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | 1.89× | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | — |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $2.2M |
| 自由现金流率自由现金流/营收 | 27.7% | 3.0% |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | $61.1M |
8季度趋势，按日历期对齐
经营现金流MLABPI
| Q1 26 | — | — | ||
| Q4 25 | $18.8M | $15.1M | ||
| Q3 25 | $8.2M | $20.9M | ||
| Q2 25 | $1.9M | $33.9M | ||
| Q1 25 | $12.7M | $-11.1M | ||
| Q4 24 | $18.1M | $12.6M | ||
| Q3 24 | $5.3M | $10.1M | ||
| Q2 24 | $10.7M | $45.5M |
自由现金流MLABPI
| Q1 26 | — | $2.2M | ||
| Q4 25 | $18.0M | $13.6M | ||
| Q3 25 | $7.1M | $18.0M | ||
| Q2 25 | $884.0K | $27.3M | ||
| Q1 25 | $11.9M | $-13.0M | ||
| Q4 24 | $17.3M | $8.5M | ||
| Q3 24 | $3.5M | $4.7M | ||
| Q2 24 | $9.9M | $44.1M |
自由现金流率MLABPI
| Q1 26 | — | 3.0% | ||
| Q4 25 | 27.7% | 14.7% | ||
| Q3 25 | 11.7% | 18.7% | ||
| Q2 25 | 1.5% | 27.9% | ||
| Q1 25 | 19.2% | -17.5% | ||
| Q4 24 | 27.6% | 9.3% | ||
| Q3 24 | 6.0% | 4.9% | ||
| Q2 24 | 16.9% | 43.0% |
资本支出强度MLABPI
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 1.6% | ||
| Q3 25 | 1.8% | 3.1% | ||
| Q2 25 | 1.7% | 6.7% | ||
| Q1 25 | 1.2% | 2.5% | ||
| Q4 24 | 1.3% | 4.5% | ||
| Q3 24 | 3.1% | 5.7% | ||
| Q2 24 | 1.5% | 1.3% |
现金转化率MLABPI
| Q1 26 | — | — | ||
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | 2.93× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | 45.56× | ||
| Q2 24 | 3.17× | 4.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
PI
暂无分部数据
